失调
肠道菌群
非酒精性脂肪肝
炎症
没食子酸表没食子酸酯
炎症性肠病
儿茶素
结肠炎
多酚
脂肪肝
医学
药理学
生物
疾病
免疫学
内科学
生物化学
抗氧化剂
作者
Guizhong Zuo,Mei-Yan Chen,Yayun Zuo,Fang Liu,Yuzhu Yang,Jie Liu,Xi Zhou,Meng-Hua Li,Jianan Huang,Liu Z,Yong Lin
标识
DOI:10.1021/acs.jafc.3c04832
摘要
Nonalcoholic fatty liver disease (NAFLD) is characterized by fat accumulation and inflammation. Epigallocatechin gallate (EGCG) has been proven to be effective against NAFLD, but its hepatoprotective mechanisms based on the "gut microbiota-barrier-liver axis" are still not fully understood. Herein, the results demonstrated that EGCG effectively ameliorated NAFLD phenotypes and metabolic disorders in rats fed a high-fat diet (HFD), and inhibited intestinal barrier dysfunction and inflammation, which is also supported in the experiment of Caco-2 cells. Moreover, EGCG could restore gut microbiota diversity and composition, particularly promoting beneficial microbes, including short-chain fatty acids (SCFAs) producers, such as Lactobacillus, and suppressing Gram-negative bacteria, such as Desulfovibrio. The microbial modulation raised SCFA levels, decreased lipopolysaccharide levels, inhibited the TLR4/NF-κB pathway, and strengthened intestinal barrier function via Nrf2 pathway activation, thereby alleviating liver steatosis and inflammation. Spearman's correlation analysis showed that 24 key OTUs, negatively or positively associated with NAFLD and metabolic disorders, were also reshaped by EGCG. Our results suggested that a combinative improvement of EGCG on gut microbiota dysbiosis, intestinal barrier dysfunction, and inflammation might be a potential therapeutic target for NAFLD.
科研通智能强力驱动
Strongly Powered by AbleSci AI